HDR brachytherapy as a single-day monotherapy: Survival results of a phase II randomized trial

被引：0
|
作者：
Jolicoeur, M. [1 ]
Derashodian, T. [1 ]
Nguyen-Huynh, T.
Hillmann, E. [1 ]
Denis, T. [1 ]
Heliou, R. [1 ]
机构：
[1] Hop Charles LeMoyne, Radiat Oncol, Greenfield Pk, PQ, Canada
来源：
RADIOTHERAPY AND ONCOLOGY | 2021年 / 158卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OC-0102
引用
下载
收藏
页码：S70 / S70
页数：1
相关论文
共 50 条
  • [1] HDR Brachytherapy as Monotherapy for Prostate Cancer: Early Toxicity of a Randomized Phase II Trial
    Jolicoeur, M.
    Derashodian, T.
    Nguyen-Huynh, T.
    Hillmann, E. de Castro
    Berbiche, D.
    Truchon, D.
    Heliou, R.
    Mondat, M.
    RADIOTHERAPY AND ONCOLOGY, 2021, 158 : S90 - S91
  • [2] HDR brachytherapy Monotherapy for prostate cancer: a one-day schedule phase II trial acute toxicity
    Jolicoeur, M.
    Nguyen, T. V.
    Derashodian, T.
    Hill, E.
    Mondat, M.
    Nachabe, M.
    Antebi, E.
    Wakil, G.
    Heliou, R.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S139 - S140
  • [3] Single Fraction HDR Brachytherapy for Prostate Cancer: SiFEPI Phase II Trial Results
    Pujol, N.
    Pace-Loscos, T.
    Schiappa, R.
    Gautier, M.
    Chand, M. E.
    Levi, J. M. Hannoun
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E242 - E242
  • [4] QoL and toxicity of HDR prostate brachytherapy as monotherapy 19Gy single fraction: phase II trial
    Gomez-Iturriaga, A.
    Casquer, F.
    Minguez, P.
    Espinosa, J.
    Bueso, A.
    Cacicedo, J.
    Fernandez, L.
    Pedraza, S.
    Garcia Escovedo, J.
    Bilbao, P.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S139 - S140
  • [5] Single fraction of HDR brachytherapy for prostate cancer: Results of the SiFEPI phase II prospective trial
    Hannoun-Levi, Jean -Michel
    Chand-Fouche, Marie-Eve
    Pace-Loscos, Tanguy
    Gautier, Mathieu
    Gal, Jocelyn
    Schiappa, Renaud
    Pujol, Nina
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2022, 37 : 64 - 70
  • [6] TOXICITY AND QUALITY OF LIFE RESULTS FROM A RANDOMIZED PHASE II TRIAL OF HDR MONOTHERAPY FOR LOW AND INTERMEDIATE-RISK PROSTATE CANCER
    Hasan, Yaser
    Loblaw, Andrew
    Chung, Hans
    McGuffin, Merrylee
    Tseng, Chia-Lin
    Mendez, Lucas
    Ravi, Ananth
    Zhang, Liying
    Mamedov, Alexandre
    Morton, Gerard
    RADIOTHERAPY AND ONCOLOGY, 2019, 139 : S36 - S36
  • [7] MR-Guided HDR Brachytherapy Boost in Localized Prostate Cancer Results of a Phase II Trial
    Johnny, C.
    Berlin, A.
    Weersink, R. A.
    Raman, S.
    Glicksman, R.
    Catton, C.
    Rink, A.
    Warde, P. R.
    Lao, B.
    Menard, C.
    Chung, P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E397 - E397
  • [8] Patient-Reported Quality of Life in Low and Intermediate Risk Prostate Cancer Patients Randomized a Phase II Randomized Trial of HDR Brachytherapy As Monotherapy (BRP2)
    Jolicoeur, M.
    Nguyen-Huynh, T. V.
    Derashodian, T.
    Hellmann, E. de Castro
    Wakil, G.
    Nachabe, M.
    Antebi, E.
    Heliou, R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : S98 - S98
  • [9] Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: A Phase II randomized trial
    Tissaverasinghe, Steven
    Crook, Juanita
    Bachand, Francois
    Batchelar, Deidre
    Hilts, Michelle
    Araujo, Cynthia
    Anderson, Danielle
    Bainbridge, Terry
    Farnquist, Brenda
    BRACHYTHERAPY, 2019, 18 (03) : 299 - 305
  • [10] Dose to the dominant intraprostatic lesion using HDR vs. LDR monotherapy: Phase II Randomized trial
    Crook, J.
    Batchelar, D.
    Hilts, M.
    Anderson, D.
    Bachand, F.
    Tissaverasinghe, S.
    Farnquist, B.
    Bainbridge, T.
    Araujo, C.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S142 - S143
12345